ketanserin has been researched along with Vascular Diseases in 4 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension." | 8.78 | Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. ( Brogden, RN; Sorkin, EM, 1990) |
| "Twenty-seven patients with untreated hypertension and/or intermittent claudication received a bolus intravenous (i." | 5.27 | Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease. ( Freitag, B; Pointel, JP; Schmitt, C; Stoltz, JF; Voisin, P; Zannad, F, 1985) |
| "Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension." | 4.78 | Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. ( Brogden, RN; Sorkin, EM, 1990) |
| "Twenty-seven patients with untreated hypertension and/or intermittent claudication received a bolus intravenous (i." | 1.27 | Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease. ( Freitag, B; Pointel, JP; Schmitt, C; Stoltz, JF; Voisin, P; Zannad, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anthony, M | 1 |
| Gerritsen, HA | 1 |
| Perquin, JW | 1 |
| de Smet, HL | 1 |
| Troost, FA | 1 |
| Kotora, OV | 1 |
| Brogden, RN | 1 |
| Sorkin, EM | 1 |
| Zannad, F | 1 |
| Voisin, P | 1 |
| Pointel, JP | 1 |
| Schmitt, C | 1 |
| Freitag, B | 1 |
| Stoltz, JF | 1 |
2 reviews available for ketanserin and Vascular Diseases
| Article | Year |
|---|---|
Serotonin antagonists.
Topics: Cyproheptadine; Depression; Ergotamine; Humans; Hypertension; Ketanserin; Lisuride; Methysergide; Mi | 1984 |
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.
Topics: Animals; Humans; Hypertension; Ketanserin; Vascular Diseases | 1990 |
2 other studies available for ketanserin and Vascular Diseases
| Article | Year |
|---|---|
Continuous imaging of regional blood flow in peripheral vascular disease using Krypton-81m: effect of Ketanserin, a new selective serotonin antagonist.
Topics: Animals; Arteriosclerosis Obliterans; Cats; Diabetic Angiopathies; Female; Humans; Hyperemia; Ketans | 1983 |
Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease.
Topics: Adult; Aged; Blood Platelets; Erythrocyte Deformability; Erythrocytes; Female; Humans; Hypertension; | 1985 |